R&D accounting treatment, firm performance, and market value: Biotech firms case study

Title: R&D accounting treatment, firm performance, and market value: Biotech firms case study
Issue: Vol. 12, No 2, 2019
Published date: 05-2019 (print) / 05-2019 (online)
Journal: Journal of International Studies
ISSN: 2071-8330, eISSN: 2306-3483
Authors: Namryoung Lee
School of Business, Korea Aerospace University, South Korea
Keywords: R&D accounting treatment, decrease in R&D capitalization, biotech, market value
DOI: 10.14254/2071-8330.2019/12-2/4
DOAJ: https://doaj.org/article/7f6b41ad34e04742a06f1b44dadac07f
Language: English
Pages: 66-81 (16)
JEL classification: M41, G32
Website: https://www.jois.eu/?513,en_rd-accounting-treatment-firm-performance-and-market-value-biotech-firms-case-study
File https://www.jois.eu/files/4_620_Namryoung%20Lee.pdf

This study examines the correlation between R&D accounting treatment and market value in association with the firm’s performance, with a focus on biotech firms. Firstly, the results of the analysis show that capitalized R&D has a positive correlation with market value, consistent with existing literature. In the case of biotech firms, capitalized R&D has a higher value relevance compared to other industries. Secondly, this study examines the effect of a decrease in capitalized R&D on market value. It is found that the decrease in capitalized R&D has a negative effect on market value, however, this is not the case for biotech firms. In particular, in years where major biotech firms acknowledge and correct their accounting error, capitalized R&D decrease seems to have a more positive effect on market value. Additionally, this study extends the inquiry in association with the company performance and finds the decrease in capitalized R&D has a significant positive association with market value when the firms get better performance. But when the firm’s performance gets worse, a decrease in capitalized R&D adversely affects the market value. However, this is not the case for biotech firms, suggesting excessive expectation around the R&D process of biotechnology firms.


1. Aboody, D., & Lev, B. (2000). Information asymmetry, R&D, and insider gains. Journal of Finance, 55(6), 2747–2767. https://doi.org/10.1111/0022-1082.00305

2. Ahmed, K., & Falk, H. (2006). The value relevance of management of research and development expenditure reporting: evidence from Australia. Journal of Accounting and Public Policy, 25(3), 231-264. https://doi.org/10.1016/j.jaccpubpol.2006.03.002

3. An, J., & Wang, X. (2010). On the influencing factors of R&D expenditures in high-tech listed companies-Based on the empirical dates (2004–2008) of listed companies. East China Economic Management, 24, 93–97. doi: http://en.cnki.com.cn/Article_en/CJFDTOTA

4. Baber, W.R., Fairfield, P.M., & Haggard, J.A. (1991). The effect of concern about reported income on discretionary spending decisions: The case of research and development, The Accounting Review, 86(4), 818-829. doi: https://www.jstor.org/stable/248158

5. Bushee, B.J. (1998). The influence of institutional investors on myopic R&D investment behavior.The Accounting Review, 73(3), 305-333. doi: https://www.jstor.org/stable/248542

6. Cazavan-Jeny, A., Jeanjean, T., & Joos, P. (2011). Accounting choice and future performance: The case of R&D accounting in France. Journal of Accounting and Public Policy, 30(2), 145–165. https://doi.org/10.1016/j.jaccpubpol.2010.09.016

7. Chambers, D., Jennings, R., & Thompson, R. (1999). Evidence on the Usefulness of “No-Discretion”Capitalization and Amortization Rules for Research and Development Costs. Working paper. http://dx.doi.org/10.2139/ssrn.58661

8. Chambers. D., Jennings, R., & Thompson, R. (2003). Managerial Discretion and Accounting for Research and Development Costs. Journal of Accounting, Auditing, and Finance, 18(1), 79-113. https://doi.org/10.1177/0148558X0301800105

9. Chan, K., Lakanishok, J., & Sougiannis, T. (2001). The stock market valuation of research and development expenditures. Journal of finance 56, 2431-2454. https://doi.org/10.1111/0022-1082.00411

10. Chan, S.H., Martin, J.D., & Kensinger, J.W. (1990). Corporate research and development expenditures and share value. Journal of Financial Economics, 26(2), 255-276. https://doi.org/10.1016/0304-405X(90)90005-K

11. Choi, J., & Lee, J. (2018). Firm size and compositions of R&D expenditures: Evidence from a panel of R&D performing manufacturing firms. Industry Innovation, 25, 459–481. doi: https://doi.org/10.1080/13662716.2017.1297222

12. Dahya. J., & McConnell, J. (2007). Board Composition, Corporate Performance and the Cadbury Committee Recommendation. Journal of Financial and Quantitative Analysis, 42, 535-564. doi: https://doi.org/10.1017/S0022109000004099

13. Dechow, P.M., & Skinner, D.J. (2000). Earnings management: Reconciling the views of accounting academics, practitioners, and regulators.Accounting Horizons, 14(2), 235-250. doi: https://doi.org/10.2308/acch.2000.14.2.235

14. Dechow, P.M., & Sloan, R.G. (1991). Executive incentives and the horizon problem.Journal of Accounting & Economics, 14(1), 51-89. doi: https://doi.org/10.1016/0167-7187(91)90058-S

15. Dinh, T., Kang, H., & Schultze, W. (2016).Capitalizing Research & Development: Signaling or Earnings Management? European Accounting Review, 25(2), 373-401. doi: https://doi.org/10.1080/09638180.2015.1031149

16. Dukes, R.E., Dyckman, T.R., & Elliot, J.A. (1980). Accounting for research and development costs: The impact on research and development expenditures. Journal of Accounting Research, 18, 1–26. doi: https://www.jstor.org/stable/2490324

17. Eberhart, A.C., Maxwell, W.F., & Siddique, A.R. (2004). An Examination of Long-Term Abnormal Stock Return and Operating Performance Following R&D Increases. The Journal of Finance, 59(2), 623-650. doi: https://doi.org/10.1111/j.1540-6261.2004.00644.x

18. Ely, K., Simko, P.J., & Thomas, L.G. (2003). The usefulness of biotechnology firms’ drug development status in the development of research and development costs. Journal of Accounting, Auditing and Finance,18(1), 163–96. doi: https://doi.org/10.1177/01485

19. García Osma, B., & Young, S. (2009). R&D expenditure and earnings targets.European Accounting Review, 18(1), 7-32.

20. doi: https://doi.org/10.1080/09638180802016718

21. Graham, J.R., Harveya, C.R., & Rajgopal, S. (2005). The economic implications of corporate financial reporting. Journal of Accounting & Economics, 40(1-3), 3-73. doi: https://doi.org/10.1016/j.jacceco.2005.01.002

22. Guo, R., Lev, B., & Zhou, N. (2005). The valuation of biotech IPOs. Journal of Accounting, Auditing & Finance 20(4), 423-459. doi: https://doi.org/10.1177/0148558X0502000407

23. Hand, J.R.M. (2005). The value relevance of financial statements in the venture capital market. The Accounting Review 80(2), 613–48. doi: https://doi.org/10.2308/accr.2005.80.2.613

24. Healy, P., Myers, S.C., & Howe, C.D. (2009). R&D Accounting and the Tradeoff between Relevance and Objectivity.

25. Working paper. doi: https://doi.org/10.1111/1475-679X.00067

26. Jensen, M C., & Meckling, W.H. (1978). Can the corporation survive? Financial Analyst Journal, Jan/Feb, l-8. 31(1), 31-

27. 37. doi: https://doi.org/10.2469/faj.v34.n1.31

28. Jin, Z., Shang, Y., & Xu, J. The impact of government subsidies on private R&D and firm performance: Does ownership matter in China’s manufacturing industry? Sustainability, 2018, 10, 2205. doi: https://doi.org/10.3390/su10072205

29. Joos, P., & Zhdanov, A. (2008). Earnings and equity valuation in the biotech industry: Theory and evidence. Financial

30. Management,37(3), 431-459. doi: https://doi.org/10.1111/j.1755-053X.2008.00020.x

31. Kaitin, K.I. (2003). Post-approval R&D raises total drug development costs to $897 million. Tufts Center for the Study of Drug Development Impact Report, 5(3). www.csdd.tufts.edu

32. Kang, P.K., & Kim, Y.C. (2016). Capitalizing R&D expenditures or expensing them all?: Evidence from the accounting environment of South Korea.International Journal of Disclosure and Governance, 13(2), 117-134. doi: https://doi.org/10.1057/jdg.2015.14

33. Khoshnevis, P. & Teirlinck, P. (2018). Performance evaluation of R&D active firms. Socio-Economic Planning Sciences, 61, 16–28. doi: https://doi.org/10.1016/j.seps.2017.01.005

34. Lev, B., & Sougiannis, T. (1996). The capitalization, amortization and value-relevance of R&D. Journal of Accounting and Economics, 21, 107–138. doi: https://doi.org/10.1016/0165-4101(95)00410-6

35. Lev, B., & Zarowin, P. (1999). The boundaries of financial reporting and how to extend them. Journal of Accounting Research, 37(2), 353–385. doi: 10.2307/2491413

36. Mande, V., File, R., & Kwak, W. (2000). Income smoothing and discretionary R&D expenditures of Japanese firms.

37. Contemporary Accounting Research, 17(2), 263-302. doi: https://doi.org/10.1506/QXBV-UY71-A6W1-FWT4

38. Markarian, G., Pozza, L., & Prencipe, A. (2008). Capitalization of R&D costs and earnings management: Evidence from Italian listed companies. The International Journal of Accounting, 43(3), 246-267. doi: https://doi.org/10.1016/j.intacc.2008.06.002

39. McConnell, J. J.,& Servaes, H. (1990). Additional Evidence on Equity Ownership and Corporate Value. Journal of Financial Economics,27, 595-612. doi: https://doi.org/10.1016/0304-405X(90)90069-C

40. Moehrle, M.G., & Walter, L. (2008). Risk and uncertainty in R&D management. R&D Management, 38(5), 449–451.

41. doi: https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1467-9310.2008.00536.x

42. Monahan, S. (1999). Conservatism, Growth and the Role of Accounting Numbers in the Equity Valuation Process. Working paper. doi: http://dx.doi.org/10.2139/ssrn.189892

43. Nelson, M., Elliott, J., & Tarpley, R. (2003). How are earnings managed? Examples from auditors. Accounting Horizons(Supplement), 17-35. doi: 10.2139/ssrn.301518

44. Nivoix, S., & Nguyen, P. (2012). Characteristics of R&D Expenditures in Japan’s Pharmaceutical Industry. Asia Pacific Business Review 18, 225–240. doi: https://doi.org/10.1080/13602381.2010.540120

45. Oswald, D.R. (2008). The determinants and value relevance of the choice of accounting for research and development expenditures in the United Kingdom. Journal of Business Finance & Accounting, 35(1-2), 1-24. doi:

46. https://doi.org/10.1111/j.1468-5957.2007.02060.x

47. Oswald, D. R., & Zarowin, P. (2007). Capitalization vs. expensing of R&D and earnings management. European Accounting Review, 16(4), 703–726. doi: https://www.researchgate.net/publication/228317439

48. Qian, H., Zhong, K., & Zhong, Z. (2012). Seasoned Equity Issuers' R&D Investments: Signaling or Over-Optimism. Journal of Financial Research, 35(4), 553-580. doi: https://doi.org/10.1111/j.1475-6803.2012.01328.x

49. Rao, A.R., & Ruekert, R.W. (1994). Brand Alliances as Signals of Product Quality. Sloan Management Review, 36 (1), 87-97. doi: http://assets.csom.umn.edu/assets/92424.pdf

50. Shehata, M. (1991). Self-selection bias and the economic consequences of accounting regulation: An application of two-stage switching regression to SFAS No. 2. The Accounting Review, 66(4), 768-787. doi: https://www.jstor.org/stable/248155

51. Simon, C.J., & Sullivan, M.W. (1993). The Measurement and Determinants of Brand Equity: A Financial Approach. Marketing Science, 12(1), 28-52. doi: https://doi.org/10.1287/mksc.12.1.28

52. Wang, Y., Du, R., Koong, K.S., & Fan, W. (2016). Effects of R&D policy choice on accounting performance and

53. market value. R&D Management, Advance online publication. https://doi.org/10.1111/radm.12225

54. Wasley, C.E., & Linsmeier, T.J. (1992). A further examination of the economic consequences of SFAS No. 2. Journal of Accounting Research, 30(1), 156-164. doi: 10.2307/2491098

55. Xu, B., Magnan, M. L., & André, P. E. (2007). The Stock Market Valuation of R&D Information in Biotech Firms.

56. Contemporary Accounting Research, 24(4), 1291–318. doi: https://doi.org/10.1506/car.24.4.10

57. Xu, J., & Sim, J. Characteristics of Corporate R&D Investment in Emerging Markets: Evidence from Manufacturing Industry in China and South Korea, Sustainability, 2018, 10(9), 3002. Doi: https://doi.org/10.3390/su10093002

58. Zakari, M., & Saidu, S. (2017). The Impact of Accounting Treatment of Research and Development Costs: Evidence from Chemring Group Plc. International Journal of Accounting, Finance and Risk Management, 2(3), 92-97. doi: https://www.researchgate.net/public

59. Zhao, R. (2002). Relative value relevance of R&D reporting: An international comparison. Journal of International Financial Management and Accounting, 13(2), 153-174. doi: https://doi.org/10.1111/1467-646X.00082